Clinical Trial

Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 23, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Alcohol dependence (AD) is a prevalent and burdensome clinical condition with high relapse rates. A central risk factor for relapse is craving for alcohol, which can be evoked by both real-world and virtual cues in immersive Virtual Reality (VR). In addition to visual and auditory stimuli, olfactory stimuli are increasingly recognized as important for creating realistic, multisensory VR environments. However, no systematic investigation has yet examined how olfactory stimuli embedded in VR-based Cue Exposure (VR-CE) influence cue-elicited craving. As part of the OLFA-VR (Effects of Olfactory Stimuli in Virtual Reality Cue Exposure on Craving in Alcohol Dependence) research project, the present feasibility study aims to evaluate the feasibility, tolerability and acceptability of implementing olfactory stimuli into VR-CE. In addition, this study not only examines the general feasibility of alcohol-related olfactory stimuli in VR-CE but also explores which specific alcohol-related olfactory stimuli prove to be feasible. The investigators hypothesize that implementing olfactory stimuli into VR-CE will be feasible and tolerable for patients with AD, with no preventable serious side effects caused by VR-CE. The investigators also hypothesize that VR-CE will induce craving in most patients.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-05-31 -> 2026-07-31 2026-06-24
minor Completion pushed: 2026-05-31 -> 2026-07-31 2026-06-24
critical Recruitment opened 2026-04-14
Trial Details
NCT Number NCT07388693
Lead Sponsor Charite University, Berlin, Germany
Conditions Alcohol Dependence
Enrollment 20 participants
Start Date 2026-03-07
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23